|Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial.|
|PMID: 19628185 Owner: NLM Status: MEDLINE|
|OBJECTIVES: We sought to determine the relationship between red blood cell (RBC) transfusion and clinical outcomes in patients undergoing primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).
BACKGROUND: The implications of RBC transfusion in patients undergoing primary PCI for AMI have not been evaluated.
METHODS: Clinical outcomes of patients from the prospective, randomized CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial were analyzed by administration of in-hospital RBC transfusion not related to coronary artery bypass surgery.
RESULTS: Of 2,060 randomized patients, 82 (3.98%) received RBC transfusion during the index hospitalization, including 33 (1.60%) with moderate/severe bleeding and 49 (2.38%) without overt major bleeding. Transfusion was independently associated with baseline anemia (odds ratio [95% confidence interval]: 4.44 [2.60 to 7.58], p < 0.0001), older age (1.03 [1.01 to 1.06], p = 0.002), triple-vessel disease (2.54 [1.47 to 4.38], p = 0.0008), and female sex (1.04 [1.02 to 1.06], p = 0.0008). Patients transfused versus not transfused had significantly higher rates of 1-year mortality (23.9% vs. 3.4%), disabling stroke (2.5% vs. 0.5%), reinfarction (7.0% vs. 2.2%), and composite major adverse cardiac events (41.0% vs. 16.6%) (all p values < 0.01). After multivariable adjustment for potential confounders including transfusion propensity, RBC transfusion was independently associated with mortality at 30 days (hazards ratio: 4.71, p = 0.0005) and 1 year (hazards ratio: 3.16, p = 0.0005).
CONCLUSIONS: An RBC transfusion after primary PCI in AMI may be harmful, which is consistent with the findings from other studies after PCI in the noninfarct setting. Alternatively, RBC transfusion may be a marker of markedly increased risk. Randomized studies are warranted to determine the optimal threshold for RBC transfusion in patients with AMI undergoing mechanical reperfusion therapy.
|Eugenia Nikolsky; Roxana Mehran; H Mehrdad Sadeghi; Cindy L Grines; David A Cox; Eulogio Garcia; James E Tcheng; John J Griffin; Giulio Guagliumi; Thomas Stuckey; Mark Turco; Martin Fahy; Alexandra J Lansky; Gregg W Stone|
Related Documents :
|24710395 - Analysis of right and left ventricular deformation in former world class swimmers - eva...
24779115 - Meaningful outcome measures in cardiac surgery.
18617475 - Clinical impact of an inter-hospital transfer strategy in patients with st-elevation my...
20802265 - Perspectives on the 2009 focused updates on the management of st-segment elevation myoc...
22248305 - Pharmacokinetics of alteplase in the treatment of ischaemic stroke.
20720345 - Assessment of coronary artery flow velocity pattern as a long-term predictor of left ve...
|Type: Journal Article; Multicenter Study; Randomized Controlled Trial|
|Title: JACC. Cardiovascular interventions Volume: 2 ISSN: 1876-7605 ISO Abbreviation: JACC Cardiovasc Interv Publication Date: 2009 Jul|
|Created Date: 2009-07-24 Completed Date: 2009-10-02 Revised Date: 2014-09-05|
Medline Journal Info:
|Nlm Unique ID: 101467004 Medline TA: JACC Cardiovasc Interv Country: United States|
|Languages: eng Pagination: 624-32 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Anemia / complications
Angioplasty, Balloon, Coronary / adverse effects*, instrumentation, mortality
Antibodies, Monoclonal / therapeutic use*
Erythrocyte Transfusion / adverse effects*, mortality
Heart Diseases / etiology
Immunoglobulin Fab Fragments / therapeutic use*
Myocardial Infarction / mortality, radiography, therapy*
Platelet Aggregation Inhibitors / therapeutic use*
Proportional Hazards Models
Severity of Illness Index
Stroke / etiology
|0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; X85G7936GV/abciximab|
|JACC Cardiovasc Interv. 2009 Jul;2(7):633-5
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I in...
Next Document: Percutaneous coronary intervention complications and guide catheter size: bigger is not better.